Anti-Angiogenese - ein Therapiekonzept zur Behandlung von Kopf-Hals-Karzinomen?[1]

Zusammenfassung

Hintergrund: Plattenepithelkarzinome des Kopf-Hals-Bereichs sind heute die sechsthäufigste Malignomerkrankung weltweit. Verbesserte Techniken in der Chirurgie, der Radiatio und der Chemotherapie konnten zwar die lokale Kontrolle von Kopf-Hals-Karzinomen verbessern, die Überlebensrate hat sich in den letzten 25 Jahren jedoch nicht signifikant verändert. Die Angiogenese gilt als eines der Schlüsselphänomene für die Progression und die Metastasierung von Kopf-Hals-Karzinomen. Inhibitoren der Angiogenese sind eine neue Klasse von anti-neoplastischen Substanzen, die eine wirkungsvolle Ergänzung konventioneller Therapieformen darstellen könnten. Material und Methode: Sowohl die Rolle der Angiogenese bei Kopf-Hals-Karzinomen als auch verschiedene aktuelle präklinische sowie klinische Studien zum Einsatz von Inhibitoren der Tumorangiogenese werden hier dargestellt und diskutiert. Ergebnisse: Zahlreiche der untersuchten Angiogenese-Inhibitoren zeigten einen antiproliferativen Effekt auf die behandelten Tumoren mit Krankheitsstabilisierungen, Regressionen der Tumormasse oder Remissionen. Schlussfolgerung: Eine anti-angiogene Therapie hat unzweifelhaft das Potential, konventionelle Therapieformen zu ergänzen. Anti-angiogene Substanzen erscheinen so als vielversprechende Therapeutika für einen klinischen Einsatz in der Behandlung von Kopf-Hals-Karzinomen.

Anti-Angiogenesis - A Treatment Strategy for Head and Neck Cancer?

Background: Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy that is now the sixth most common neoplasm in the world. Despite numerous advances in treatment, the long-term survival has remained the same for the last 25 years. Angiogenesis has been shown to be important for HNSCC tumour growth and metastasis. Therefore, inhibitors of angiogenesis are a new class of anti-nepolastic substances that might be a powerful complement to conventional therapy in HNSCC. Material and Methods: The role of angiogenesis in HNSCC as well as preclinical and clinical trials concerning inhibitors of tumor-angiogenesis are discussed here. Results: Many of the investigated angiogenesis inhibitors demonstrated anti-tumor effects in preclinical and clinical trials. In a few cases, partial remission was observed. Conclusions: Anti-angiogenic therapy will undoubtly have the potential to change standard tumor therapies. Some anti-angiogenic substances appear to be promising candidates for a clinical use in the therapy of HNSCC.

Angiogenese - Kopf-Hals-Karzinome - Anti-Angiogenese

Angiogenesis - Head and neck cancer - Anti-angiogenesis

Literatur

• 1 Lingen M W. Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents.  Crit Rev Oral Biol Med. 1999;  10 153-164
• 2 Mashberg A. Head and neck cancer.  N Engl J Med. 1993;  328 1783-1784
• 3 Boyle P, Macfarlane G J, Zheng T, Maisonneuve P, Evstifeeva T, Scully C. Recent advances in epidemiology of head and neck cancer.  Curr Opin Oncol. 1992;  4 471-477
• 4 Dimery I W, Hong W K. Overview of combined modality therapies for head and neck cancer.  J Natl Cancer Inst. 1993;  85 95-111
• 5 Boring C C, Squires T S, Tong T, Montgomery S. Cancer statistics, 1994.  CA Cancer J Clin. 1994;  44 7-26
• 6 Hong W K, Bromer R H, Amato D A, Shapshay S, Vincent M, Vaughan C, Willett B, Katz A, Welch J, Fofonoff S. Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy.  Cancer. 1985;  56 1242-1245
• 7 Day G L, Blot W J, Shore R E, Schoenberg J B, Kohler B A, Greenberg R S, Liff J M, Preston-Martin S, Austin D F, McLaughlin J K. Second cancers following oral and pharyngeal cancer: patients’ characteristics and survival patterns.  Eur J Cancer B Oral Oncol. 1994;  30 381-386
• 8 Larson J T, Adams G L, Fattah H A. Survival statistics for multiple primaries in head and neck cancer.  Otolaryngol Head Neck Surg. 1990;  103 14-24
• 9 Folkman J, Shing Y. Angiogenesis.  J Biol Chem. 1992;  267 10 931-10 934
• 10 Risau W. Mechanisms of angiogenesis.  Nature. 1997;  386 671-674
• 11 Marmé D. Tumorangiogenese: Molekulare Fakten und therapeutische Möglichkeiten.  Chirurg. 1999;  70 30-35
• 12 Pepper M S. Manipulating angiogenesis: from basic science to the bedside.  Arterioscler Thromb Vasc Biol. 1997;  17 605-619
• 13 Folkman J. Tumour angiogenesis.  Adv Cancer Res. 1985;  43 175-203
• 14 Folkman J, Klagsbrun M. Angiogenetic Factors.  Science. 1987;  235 442-447
• 15 Liotta L A. Tumor invasion: role of the extracellular matrix.  Cancer Res. 1986;  46 1-7
• 16 Petruzelli G J, Snyderman C H, Johnson J T, Myers E N. Angiogenesis induced by head and neck squamous cell carcinoma xenografts in the chick embryo chorioallantioc membrane model.  Ann Otol Rhinol Laryngol. 1993;  102 212-221
• 17 Kühn R, Rojas W, Riedel F, Bergler W, Hörmann K. Tumour angiogenesis in head and neck squamous cell carcinoma.  Br J Cancer. 1998;  77 27
• 18 Pazouki S, Chisholm D M, Adi M M, Carmichael G, Farquharson M, Ogden G R, Schor S L, Schor A M. The association between tumour progression and vascularity in the oral mucosa.  J Pathol. 1997;  183 39-43
• 19 Gleich L L, Biddinger P W, Duperier F D, Gluckman J L. Tumor angiogenesis as a prognostic indicator in T2-T4 oral cavity squamous cell carinoma: a clinical-pathologic correlation.  Head and Neck. 1997;  19 276-280
• 20 Dray T G, Hardin N J, Sofferman R A. Angiogenesis as a prognostic marker in early head and neck cancer.  Ann Otol Rhinol Laryngol. 1995;  104 724-729
• 21 Beatrice F, Cammarota R, Giordano C, Corrado S, Ragona R, Sartoris A, Bussolino F, Valente G. Angiogenesis: prognostic significance in laryngeal cancer.  Anticancer Res. 1998;  18 4737-4740
• 22 Murray J D, Carlson G W, McLaughlin K, Pennington M, Lynn M, DeRose P B, Williams J K, Cohen C. Tumor angiogenesis as a prognostic factor in laryngeal cancer.  Am J Surg. 1997;  174 523-526
• 23 Penfold C N, Partridge M, Rojas R, Langdon J D. The role of angiogenesis in the spread of oral squamous cell carcinoma.  Br J Oral Maxillofac Surg. 1996;  34 37-41
• 24 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor.  Endocr Rev. 1997;  18 4
• 25 Heits F, Wiedemann G J, Jelkmann W. Vascular endothelial growth factor VEGF stimulates angiogenesis in good and bad situations.  Dtsch Med Wochenschr. 1998;  123 259-265
• 26 Siemeister G, Martiny-Baron G, Marmé D. The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities.  Cancer Metastasis Rev. 1998;  17 241
• 27 Riedel F, Götte K, Bergler W, Rojas W, Hörmann K. Expression of basic fibroblast growth factor and its down-regulation by interferons in head and neck cancer.  Head Neck. 2000;  22 183-189
• 28 Riedel F, Götte K, Oulmi Y, Bergler W, Hörmann K. Immunocytochemical localization of basic fibroblast growth factor in squamous cell carcinoma of the head and neck.  Anticancer Res. (im Druck)
• 29 Riedel F, Götte K, Schwalb J, Bergler W, Hörmann K. Ko-Expression von bFGF und VEGF korreliert mit erhöhter Gefäßdichte in Kopf-Hals-Karzinomen.  Laryngo-Rhino-Otol. 2000;  79 730-735
• 30 Riedel F, Götte K, Schwalb J, Schäfer C, Hörmann K. Expresson of vascular endothelial growth factor correlates with angiogenesis and p53 mutations in head and neck squamous cell carcinoma.  Acta Oto-Laryngol. 2000;  120 105-111
• 31 Riedel F, Götte K, Schwalb J, Wirtz H, Bergler W, Hörmann K. Serum levels of vascular endothelial growth factor in patients with head and neck cancer.  Eur Arch Oto-Rhino-Laryngol. 2000;  257 332-336
• 32 Dietz A, Rudat V, Conradt C, Weidauer H, Ho A, Moehler T. Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy.  Head Neck. 2000;  22 666-673
• 33 Schmidt M, Polednik C, Hoppe F. Proteolytic patterns of head and neck squamous cell carcinoma.  Eur Arch Otorhinolaryngol. 1999;  256 346-350
• 34 Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, Takeuchi H, Shirasuna K. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis.  Head Neck. 1999;  21 627-638
• 35 Charous S J, Stricklin G P, Nanney L B, Netterville J L, Burkey B B. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma.  Ann Otol Rhinol Laryngol. 1997;  106 271-278
• 36 Schnapper H W, Grant D S, Stetler-Stevenson W G. Type IV collagenases and TIMPs modulate endothelial cell morphogenesis in vitro.  J Cell Physiol. 1993;  156 235-246
• 37 Riedel F, Götte K, Schwalb J, Hörmann K. Expression of 92-kD Type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma.  Int J Oncol. 2000;  17 1099-1105
• 38 Schiefer D, Gottstein C, Diehl V, Engert A. Anti-angiogenesis: a new approach to tumor therapy?.  Med Klin. 1999;  94 570-579
• 39 Boehm T, Folkman J, Browder T, O’Reilly M S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.  Nature. 1997;  390 404-407
• 40 Jain R K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors.  Cancer Metastasis Rev. 1990;  9 253-266
• 41 Augustin H G. Antiangiogenic tumour therapy: will it work?.  Trends Pharmacol Sci. 1998;  19 216-222
• 42 Jaeger T M, Knoll M R, Sturm J W, Winkler M, Post S. Therapeutic influences on angiogenesis. “From bench to bedside”.  Dtsch Med Wochenschr. 1999;  124 121-123
• 43 Kudelka A P, Levy T, Verschraegen C F, Edwards C L, Piamsomboon S, Termrungruanglert W, Freedman R S, Kaplan A L, Kieback D G, Meyers C A, Jaeckle K A, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang R A, Gutterman J U, Kavanagh J J. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.  Clin Cancer Res. 1997;  3 1501-1505
• 44 Ueda N, Kamata N, Hayashi E, Yokoyama K, Hoteiya T, Nagayama M. Effects of an anti-angiogenic agent, TNP-470, on the growth of oral squamous cell carcinomas.  Oral Oncol. 1999;  35 554-560
• 45 Heath E I, Grochow L B. Clinical potential of matrix metalloprotease inhibitors in cancer therapy.  Drugs. 2000;  59 1043-1055
• 46 Millauer B, Shawver K L, Plate K H, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.  Nature. 1994;  367 576
• 47 Kondo S, Asano M, Suzuki H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.  Biochem Biophys Res Commun. 1993;  194 1234-1241
• 48 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.  Cell. 1996;  86 353
• 49 Saleh M, Stacker S A, Wilks A F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.  Cancer Res. 1996;  56 393-401
• 50 Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig N E. Halting angiogenesis suppresses carcinoma cell invasion.  Nature Med. 1997;  3 1222-1227
• 51 Mendel D B, Laird A D, Smolich B D, Blake R A, Liang C, Hannah A L, Shaheen R M, Ellis L M, Weitman S, Shawver L K, Cherrington J M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.  Anticancer Drug Des. 2000;  15 29-41
• 52 Laird A D, Vajkoczy P, Shawver L K, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard S R, Blake R A, Fong T A, Strawn L M, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth K P, McMahon G, Cherrington J M. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.  Cancer Res. 2000;  60 4152-4160
• 53 Wood J M, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O’Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch K H, Schneider M R, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 222 584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.  Cancer Res. 2000;  60 2178-2189
• 54 O’Reilly M S, Boehm T, Shing Y, Fukai N, Vasios G, Lane W S, Flynn E, Birkhead J R, Olsen B R, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.  Cell. 1997;  88 277-285
• 55 O’Reilly M S, Holmgren L, Shing Y, Chen C, Rosenthal R A, Moses M, Lane W S, Cao Y, Sage E H, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.  Cell. 1994;  79 315-328
• 56 Riedel F, Li M, Sheng C, Drenning S, Grandis J R. Combined treatment of HNSCC tumor xenografts with anti-angiogenic endostatin and EGFR antisense gene therapy. 92^nd Annual Meeting of the American Association for Cancer Research (AACR), New Orleans, USA, 24.-28. März 2001. 

1 Herrn Prof. Dr. med. Ulrich Koch zum 60. Geburtstag gewidmet.